Obstacles to improving outcomes in the treatment of uveal melanoma

被引：19
作者：
Tsai, Katy K. [1 ]
Bollin, Kathryn B. [2 ]
Patel, Sapna P. [3 ]
机构：
[1] Univ Calif San Francisco, Cutaneous Oncol, Hellen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Scripps Clin, Div Hematol & Oncol, La Jolla, CA 92037 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA
来源：
CANCER | 2018年 / 124卷 / 13期
基金：
美国国家卫生研究院;
关键词：
barriers; challenges; outcomes; success; therapy; treatment; trials; uveal melanoma; INTRAARTERIAL HEPATIC FOTEMUSTINE; DEPENDENT PROBE AMPLIFICATION; GENE-EXPRESSION PROFILE; LIVER METASTASES; CHOROIDAL MELANOMA; DOUBLE-BLIND; PROGNOSTIC IMPLICATIONS; UNTREATED MELANOMA; COMPLETE RESECTION; TUMOR DIAMETER;
D O I：
10.1002/cncr.31284
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The rate of advances in uveal melanoma has not kept pace with the rate of advances in cutaneous melanoma. Many patients lack access to or knowledge of specialty centers, and integrated multidisciplinary care between ophthalmology, radiation oncology, and medical oncology is far from the norm. This treatment isolation leads to limited communication about novel clinical trial opportunities. Clinical trials themselves are not widely available, and a lack of robust funding limits rapid and complete investigations. This review outlines the obstacles to success in uveal melanoma management and highlights strategies for overcoming these challenges. (C) 2018 American Cancer Society.
引用
收藏
页码：2693 / 2703
页数：11
相关论文
共 82 条
  • [1] Clinical Outcomes in Metastatic Uveal Melanoma Treated With PD-1 and PD-L1 Antibodies
    Algazi, Alain P.
    Tsai, Katy K.
    Shoushtari, Alexander N.
    Munhoz, Rodrigo R.
    Eroglu, Zeynep
    Piulats, Josep M.
    Ott, Patrick A.
    Johnson, Douglas B.
    Hwang, Jimmy
    Daud, Adil I.
    Sosman, Jeffrey A.
    Carvajal, Richard D.
    Chmielowski, Bartosz
    Postow, Michael A.
    Weber, Jeffrey S.
    Sullivan, Ryan J.
    [J]. CANCER, 2016, 122 (21) : 3344 - 3353
  • [2] Expression of Fas and Fas ligand in uveal melanoma: biological implication and prognostic value
    Anastassiou, G
    Coupland, SE
    Stang, A
    Boeloeni, R
    Schilling, H
    Bornfeld, N
    [J]. JOURNAL OF PATHOLOGY, 2001, 194 (04) : 466 - 472
  • [3] Aoyama T, 2000, CANCER, V89, P1561, DOI 10.1002/1097-0142(20001001)89:7<1561::AID-CNCR21>3.0.CO
  • [4] 2-R
  • [5] Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
    Ascierto, Paolo A.
    Del Vecchio, Michele
    Robert, Caroline
    Mackiewicz, Andrzej
    Chiarion-Sileni, Vanna
    Arance, Ana
    Lebbe, Celeste
    Bastholt, Lars
    Hamid, Omid
    Rutkowski, Piotr
    McNeil, Catriona
    Garbe, Claus
    Loquai, Carmen
    Dreno, Brigitte
    Thomas, Luc
    Grob, Jean-Jacques
    Liszkay, Gabriella
    Nyakas, Marta
    Gutzmer, Ralf
    Pikiel, Joanna
    Grange, Florent
    Hoeller, Christoph
    Ferraresi, Virginia
    Smylie, Michael
    Schadendorf, Dirk
    Mortier, Laurent
    Svane, Inge Marie
    Hennicken, Delphine
    Qureshi, Anila
    Maio, Michele
    [J]. LANCET ONCOLOGY, 2017, 18 (05) : 611 - 622
  • [6] Molecular pathways mediating liver metastasis in patients with uveal melanoma
    Bakalian, Silvin
    Marshall, Jean-Claude
    Logan, Patrick
    Faingold, Dana
    Maloney, Shawn
    Di Cesare, Sebastian
    Martins, Claudia
    Fernandes, Bruno F.
    Burnier, Miguel N., Jr.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (04) : 951 - 956
  • [7] Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative
    Bogaerts, Jan
    Sydes, Matthew R.
    Keat, Nicola
    McConnell, Andrea
    Benson, Al
    Ho, Alan
    Rotha, Arnaud
    Fortpied, Catherine
    Eng, Cathy
    Peckitt, Clare
    Coens, Corneel
    Pettaway, Curtis
    Arnold, Dirk
    Hall, Emma
    Marshall, Ernie
    Sclafani, Francesco
    Hatcher, Helen
    Earl, Helena
    Ray-Coquard, Isabelle
    Paul, James
    Blay, Jean-Yves
    Whelan, Jeremy
    Panageas, Kathy
    Wheatley, Keith
    Harrington, Kevin
    Licitra, Lisa
    Billingham, Lucinda
    Hensley, Martee
    McCabe, Martin
    Patel, Poulam M.
    Carvajal, Richard
    Wilson, Richard
    Glynne-Jones, Rob
    McWilliams, Rob
    Leyvraz, Serge
    Rao, Sheela
    Nicholson, Steve
    Filiaci, Virginia
    Negrouk, Anastassia
    Lacombe, Denis
    Dupont, Elisabeth
    Pauporte, Iris
    Welch, John J.
    Law, Kate
    Trimble, Ted
    Seymour, Matthew
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (03) : 271 - 281
  • [8] Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)
    Carvajal, Richard D.
    Schwartz, Gary K.
    Mann, Helen
    Smith, Ian
    Nathan, Paul D.
    [J]. BMC CANCER, 2015, 15
  • [9] Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma A Randomized Clinical Trial
    Carvajal, Richard D.
    Sosman, Jeffrey A.
    Quevedo, Jorge Fernando
    Milhem, Mohammed M.
    Joshua, Anthony M.
    Kudchadkar, Ragini R.
    Linette, Gerald P.
    Gajewski, Thomas F.
    Lutzky, Jose
    Lawson, David H.
    Lao, Christopher D.
    Flynn, Patrick J.
    Albertini, Mark R.
    Sato, Takami
    Lewis, Karl
    Doyle, Austin
    Ancell, Kristin
    Panageas, Katherine S.
    Bluth, Mark
    Hedvat, Cyrus
    Erinjeri, Joseph
    Ambrosini, Grazia
    Marr, Brian
    Abramson, David H.
    Dickson, Mark Andrew
    Wolchok, Jedd D.
    Chapman, Paul B.
    Schwartz, Gary K.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (23): : 2397 - 2405
  • [10] Oncology Meets Immunology: The Cancer-Immunity Cycle
    Chen, Daniel S.
    Mellman, Ira
    [J]. IMMUNITY, 2013, 39 (01) : 1 - 10
123456789